Affordable Access

Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme.

Authors
  • Hakin-Smith, V
  • Jellinek, D A
  • Levy, D
  • Carroll, T
  • Teo, M
  • Timperley, W R
  • McKay, M J
  • Reddel, R R
  • Royds, J A
Type
Published Article
Journal
Lancet (London, England)
Publication Date
Mar 08, 2003
Volume
361
Issue
9360
Pages
836–838
Identifiers
PMID: 12642053
Source
Medline
License
Unknown

Abstract

Despite advances in the molecular pathogenesis of glioblastoma multiforme, no reliable prognostic markers have been identified. We analysed telomerase activity and telomere lengths in glioblastoma multiformes from 77 patients. 19 patients (25%) had tumours with the alternative-lengthening-of-telomere (ALT) phenotype. Median survival for patients with this phenotype was 542 days (95% CI 114-970) compared with 247 days (224-270) for glioblastoma multiformes with normal telomeres (p=0.0003). Cox's regression analysis showed that this association is independent of age. In patients with non-ALT tumours, telomerase activity did not affect survival (median 287 [199-375] vs 236 [230-242] days, p=0.275). We conclude that ALT is a prognostic indicator for patients with glioblastoma multiforme.

Report this publication

Statistics

Seen <100 times